Drug
Lenacapavir long-acting
Lenacapavir long-acting is a pharmaceutical drug with 4 clinical trials. Currently 4 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
4(100%)
Phase Distribution
Ph not_applicable
1
25%
Ph phase_4
2
50%
Ph phase_1
1
25%
Phase Distribution
1
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
4
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Recruiting2
Active, not recruiting2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
4
Success Rate
N/A
Most Advanced
Phase 4
Trials by Phase
Phase 11 (25.0%)
Phase 42 (50.0%)
N/A1 (25.0%)
Trials by Status
recruiting250%
active_not_recruiting250%
Recent Activity
4 active trials
Showing 4 of 4
active_not_recruitingphase_4
Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting
NCT07210125
recruitingnot_applicable
ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention
NCT07497594
recruitingphase_4
Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP
NCT07218211
active_not_recruitingphase_1
A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV
NCT06970223
Clinical Trials (4)
Showing 4 of 4 trials
NCT07210125Phase 4
Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting
NCT07497594Not Applicable
ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention
NCT07218211Phase 4
Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP
NCT06970223Phase 1
A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4